CRISPR−Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trial

, and no prolonged high-grade cytopenias were observed. The most common adverse events were cytopenias and infections. Three cases of transplant-related mortality were observed due to renal failure, sepsis and sinusoidal obstruction syndrome, respectively. In summary, trem-cel demonstrated safe, rapid, robust engraftment, and GO maintenance was administered without prolonged hematologic toxicity. ClinicalTrials.gov identifier: NCT04849910 .

Authors

Institutions

Publication Details

Journal
Nature Medicine
Published
2026-05-12
DOI
https://doi.org/10.1038/s41591-026-04362-1
Primary Topic
Acute Myeloid Leukemia Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

CRISPR−Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trial

Brenda Cooper, Sanjana Thosar, Sharon L. Hyzy, Muhammad Umair Mushtaq et al.
Nature Medicine
Acute Myeloid Leukemia Research
article

CRISPR−Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trial

Brenda Cooper, Sanjana Thosar, Sharon L. Hyzy, Muhammad Umair Mushtaq, Hyung C. Suh, Darren Stanizzi, Guy Mundelboim, Glen Raffel, Juliana Xavier-Ferrucio, Michael R. Loken, Bin E. Li, J. DiPersio, Léa Bernard, Deborah Lloyd, Chad Hudson, Christopher A. Slapak, Guangwu Guo, Huanying Gary Ge, Joseph Rimando, Vanessa E. Kennedy, Joseph Maakaron, Guenther Koehne, Sagar S. Patel, Michelle I. Lin, Melissa M. Lee-Sundlov, Roni Tamari, Nirali N. Shah, Divya Koura
article en

Abstract

, and no prolonged high-grade cytopenias were observed. The most common adverse events were cytopenias and infections. Three cases of transplant-related mortality were observed due to renal failure, sepsis and sinusoidal obstruction syndrome, respectively. In summary, trem-cel demonstrated safe, rapid, robust engraftment, and GO maintenance was administered without prolonged hematologic toxicity. ClinicalTrials.gov identifier: NCT04849910 .

Nature Medicine
Baptist Hospital of Miami (US), National Institutes of Health (US), University of Minnesota (US), Hackensack University Medical Center (US), Memorial Sloan Kettering Cancer Center (US), Emory University (US), Washington University in St. Louis (US), UC San Diego Health System (US), Huntsman Cancer Institute (US), Hôpital Maisonneuve-Rosemont (CA), The University of Kansas Cancer Center (US), Baptist Health South Florida (US), University Hospitals Seidman Cancer Center (US), Stanford Blood Center (US), National Cancer Institute (US), Center for Cancer Research (US), Moores Cancer Center
Good health and well-being
Openalex Percentile: Top 5%
Acute Myeloid Leukemia Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.